Gensight Biologics S Ais A Clinical Stage Biopharma Company Based In Parisfrancefounded In 2012The Company Focuses On Developing And Commercializing Innovative Gene Therapies For Retinal Neurodegenerative Diseases And Central Nervous System Disordersits Mission Is To Create Novel Treatments For Severe Inherited Diseases Affecting The Eye And Central Nervous System The Company Utilizes Two Main Technology Platformsthe Mitochondrial Targeting Sequencemtsand Optogeneticsthese Technologies Support Its Gene Therapy Approachwhich Aims To Preserve Or Restore Vision Through Single Intravitreal Injectionsgensight Biologics Has Several Product Candidatesincluding Lumevoqa Gene Therapy For Leber Hereditary Optic Neuropathyand Gs030Which Is In Clinical Trials For Retinitis Pigmentosa Gensight Biologics Collaborates With Various Institutionsincluding Sorbonne Universitaand Novartis Pharma Agto Advance Its Research And Product Developmentthe Company Is Led By Ceo Laurence Rodriguez And Operates With A Specialized Team Dedicated To Biotechnology Research
